Arecor Presents Positive Data from US Phase I Clinical Trial of Ultra-Rapid Acting Insulin Candidate AT247

- Data presented at the American Diabetes Association 83rd Scientific Sessions - AT247 delivers significantly accelerated insulin absorption and early exposure (PK profile) compared with NovoLog® and Fiasp® - Further supports potential to enable more effective disease management for people with Type I diabetes via fully automated closed loop insulin pump delivery (artificial pancreas)

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that positive results from its second Phase I clinical trial investigating ultra-rapid acting insulin product candidate, AT247, have been shared in a poster presentation at the American Diabetes Association (ADA) 83rd Scientific Sessions meeting, being held until today in San Diego, California and online. 

The poster, “Double blind cross over study of ultra-rapid AT247 compared with NovoLog® and Fiasp® during continuous subcutaneous infusion (CSII) assessed by a hyperinsulinemic euglycemic clamp”, is displayed in the meeting’s Poster Hall and available as an ePoster for virtual attendees. 

Dr Marcus Hompesch, MD. President and Chief Executive Officer of ProSciento Inc, said: “AT247 has demonstrated faster insulin absorption when delivered by continuous infusion via an insulin pump, compared to other rapid acting insulins currently available to patients. Its PK profile offers the potential to further improve blood glucose control, and may play an important role in facilitating a fully closed loop artificial pancreas – a life changing treatment approach for people living with diabetes.” 

Sarah Howell, Chief Executive Officer of Arecor, added: “These data reinforce AT247’s potential to enable even more effective disease management for people with Type I diabetes. The availability of a truly ultra-rapid acting insulin will be a key component in the move towards a fully closed loop artificial pancreas system, a potentially life changing treatment option for people living with diabetes, improving health outcomes and reducing the significant burden of managing this chronic disease. With AT247, Arecor has the ability to significantly advance the diabetic treatment landscape and, ultimately, deliver better health outcomes for patients.” 

AT247 is a 100U/mL ultra-rapid acting novel formulation of insulin that has been designed to accelerate the absorption of insulin following subcutaneous injection, to enable more effective management of blood glucose levels for people living with diabetes. 

In the Phase I trial, faster absorption of AT247 resulted in higher early insulin exposure than with gold standard insulins NovoLog® and Fiasp® following bolus dose delivery during continuous subcutaneous infusion. The demonstrated PK profile of AT247 supports further investigation into its potential to further improve automated insulin delivery and builds on the superior PK/PD profile of a single AT247 dose compared with NovoLog® and Fiasp®, previously demonstrated in an earlier Phase I study. 

Headline results from the ARE-AT247-103 clinical trial were announced by the Company on 11 October 2022. 


Article source: arecor.com
Published on: 26/06/2023